Curated News
By: NewsRamp Editorial Staff
November 09, 2026
Regentis Inks Exclusive Israel Distribution Deal for GelrinC
TLDR
- Regentis gains a four-year exclusive Israeli distribution deal for GelrinC, with AMI driving surgeon adoption and initial revenue expected in 2027.
- AMI will commercialize GelrinC in Israel under Ministry of Health approval, with minimum purchase requirements and joint work to secure reimbursement from health maintenance organizations.
- The agreement expands access to an off-the-shelf implant that helps regenerate damaged knee cartilage, offering patients a new option to restore mobility and quality of life.
- GelrinC is a cell-free hydrogel implant that erodes in the knee and lets surrounding cells regrow cartilage through a controlled, synchronized process.
Impact - Why it Matters
This news matters because it marks a significant step toward commercializing a novel, off-the-shelf solution for knee cartilage repair—a condition affecting hundreds of thousands of patients annually in the U.S. alone. The partnership with AMI Medical Technologies not only provides Regentis with immediate access to Israel’s orthopedic market but also lays the groundwork for reimbursement coverage, which is critical for patient access and widespread adoption. As Regentis continues its Phase 3 trial in the U.S., success in Israel could accelerate regulatory and commercial momentum globally, offering hope for a simpler, more accessible alternative to current treatments that often require multiple procedures or lack off-the-shelf options.
Summary
Regentis Biomaterials (NYSE American: RGNT), a regenerative medicine company specializing in tissue repair, has signed a four-year exclusive distribution agreement with AMI Medical Technologies Ltd. to commercialize GelrinC® in Israel. GelrinC is Regentis’ proprietary off-the-shelf hydrogel implant designed to repair damaged knee cartilage. It has received regulatory approval from Israel’s Ministry of Health for the same indication approved in Europe and currently being pursued in the United States. Under the agreement, AMI Medical Technologies will leverage its established relationships with orthopedic surgeons, hospitals, and clinics to drive the product’s commercial introduction. The deal includes minimum purchase requirements, and Regentis expects initial revenue contributions beginning in 2027.
Beyond distribution, the two companies will collaborate to secure reimbursement coverage for GelrinC with Israel’s leading health maintenance organizations and to promote adoption among orthopedic surgeons treating patients with focal cartilage defects. Until reimbursement is established, patients may access the implant through private health insurance. This agreement supports Regentis’ broader commercialization efforts in Europe and Israel as the company continues advancing its pivotal Phase 3 clinical program in the United States. GelrinC is a cell-free, off-the-shelf hydrogel that is eroded and resorbed in the knee, allowing surrounding cells to regenerate cartilage in a controlled and synchronous process. Regentis aims to address a U.S. market of approximately 470,000 cartilage knee repair cases annually where no off-the-shelf treatment is available. To view the full press release, visit https://ibn.fm/t1dw4. For investor updates, the company’s newsroom is available at https//ibn.fm/RGNT.
Source Statement
This curated news summary relied on content distributed by InvestorBrandNetwork (IBN). Read the original source here, Regentis Inks Exclusive Israel Distribution Deal for GelrinC
